Use of Virtual Reality Mask During Blood and Skin Allergic Tests in 7 to 13 Children (REVAPRICK)

May 16, 2022 updated by: University Hospital, Clermont-Ferrand

Evaluation of the Use of a Virtual Reality Mask During Blood Tests and Prick Tests Performed in Allergic Children Aged 7 to 13 Years: a Multicenter, Randomized Trial

Main objective :

Evaluate the effect of using a virtual reality mask during the blood test and pricks tests in allergic children aged from 7 to 13 years.

Hypothesis :

Using virtual reality mask during blood test and pricks tests for allergic kids from 7 to 13 would reduce anxiety and pain

Study Overview

Detailed Description

Investigation of food or respiratory allergy is based on prick tests and serum specific immunoglobulin E assays. The nurse often controls the blood test pain but during the skin tests, many children cry, feeling both fear and pain. This traumatic experience will in most cases be repeated during the child's allergic follow-up.

To date, there are few effective means of limiting anxiety and pain associated with prick tests and therefore little research work on this subject.

Immersion in virtual reality (VR) seems to be an interesting way of distraction for children from 7 to 13 years needing this treatment. Indeed, it makes it possible to saturate the sensorially of the child thus reducing the nociceptive perceptions and the anxiety. The choice of VR mask with pediatric program specific seems interesting for this children This is a randomized, open-label, two-armed parallel, multicenter therapeutic trial comparing an analgesic strategy using authorized medical devices (conventional strategy) with a virtual reality mask distraction technique for allergics tests in children from 7 to 13 years old hospitalized in the pediatric consultation of Clermont Ferrand University Hospital and in the day hospital of Saint-Etienne University Hospital

The control arm is the local anesthetic cream (for the blood test) arm with distraction from nurse/parents +/-anesthesic and anxiolytic gas and the experimental arm is the local anesthetic cream + virtual reality mask distraction

The nurse informs and obtains the consent of the child and his parents. Then she measures child's pain and anxiety before the care, during the blood test, at the third prick test and immediately after the care.

She also notes the anxiety of the parents before and after the care. Finally, the satisfaction of the child, parents, nurses will be collected at the end of the care.

After statistical analysis of these two arms, it will be possible to determine the value of the virtual reality mask to reduce the child's pain and anxiety during the pricks tests.

Study Type

Interventional

Enrollment (Anticipated)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Clermont-Ferrand, France, 63000
        • CHU de Clermont-Ferrand
      • Saint-Étienne, France, 42000
        • CHU de Saint Etienne
        • Principal Investigator:
          • Christine REDURON

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years to 13 years (CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children from 7 to 13 years old requiring blood test and prick tests in pediatric consultation at the Clermont-Ferrand University Hospital and in the pediatric's day hospital at the Saint-Etienne University Hospital
  • Subjects and their parents who were informed about the study and gave informed consent
  • Enrollment in the Social Security system
  • Children and parents able to use the self-report scales proposed in the study

Exclusion Criteria:

Children from 7 to 13 :

  • presenting a contraindication to the use of the virtual reality mask: heart disease, epilepsy, psychiatric illness (major anxiety, post-traumatic stress disorder)
  • Having a modification of pain's integration (spina bifida for example)
  • Having received an analgesic before the care
  • Requiring contact isolation
  • With a history of seizures or motion sickness
  • Refusal of the parents and/or the child

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: standard
Use local anesthesic cream + nurse or parents distraction +/- anesthesic or anxiolytic gas
usual process
EXPERIMENTAL: virtual reality
Use local anesthesic cream and virtual reality mask
virtual reality mask Deepsen® with age-appropriate software Birdy®

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
children's pain hetero-evaluation
Time Frame: during blood test
children's pain evaluation by the nurse with the visual analog scale quote from 0 to 10, 10=worst score
during blood test
children's pain hetero-evaluation
Time Frame: during procedure (prick test)
children's pain evaluation by the nurse with the visual analog scale from 0 to 10, 10= worst score
during procedure (prick test)
children's pain self-evaluation
Time Frame: 5 min after the care
self evaluation of children's pain with the visial analog scale in vertical position quote from 0 to 10, 10=worst score
5 min after the care

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change from baseline children's anxiety at just after the care
Time Frame: before the care and 5 min after the care
self-evaluation of children's anxiety with the scale "child fear scale" quote from 0 to 4, 4= worst score
before the care and 5 min after the care
children's anxiety hetero evaluation
Time Frame: during blood test
children's anxiety evaluation by the nurse with the scale "child fear scale" quote from 0 to 4, 4= worst score
during blood test
children's anxiety hetero evaluation
Time Frame: during procedure (prick tests)
children's anxiety evaluation by the nurse with the scale "child fear scale" quote from 0 to 4, 4= worst score
during procedure (prick tests)
change from baseline parents' anxiety at just after the care
Time Frame: before the care and 5 min after the care
self-evaluation of parents' anxiety with the numerical scale quote from 1 to 10, 10= worst score
before the care and 5 min after the care
evaluation of the care
Time Frame: 5 min after the care
satisfaction of the care for children, parents and nurses with satisfaction questionnaire for children : a score from 1 to 3 (3=best score, very satisfied) for parents with a score from 1 to 5 (5= best score, very satisfied) and for nurse with a score from 1 to 5 (5= best score, very satisfied)
5 min after the care

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

June 1, 2022

Primary Completion (ANTICIPATED)

June 1, 2025

Study Completion (ANTICIPATED)

June 1, 2025

Study Registration Dates

First Submitted

May 2, 2022

First Submitted That Met QC Criteria

May 16, 2022

First Posted (ACTUAL)

May 18, 2022

Study Record Updates

Last Update Posted (ACTUAL)

May 18, 2022

Last Update Submitted That Met QC Criteria

May 16, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Testicular Diseases

Clinical Trials on control arm

3
Subscribe